Actualités New River Pharmaceuticals (MM) - NRPH | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite Indices

NEW YORK, April 18 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced...

New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013

RADFORD, Va., April 3 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced that, in connection with its...

New River Announces Expiration of Hart-Scott-Rodino Waiting Period

RADFORD, Va., March 19 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced that the waiting period under the...

New River Pharmaceuticals Announces Year-End Results

RADFORD, Va., March 13 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced its financial results for the year...

Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine

BASINGSTOKE, England, PHILADELPHIA, Pennsylvania and Radford, VIRGINIA, February 23 /PRNewswire-FirstCall/ -- Shire plc...

New River Pharmaceuticals to be Acquired by Shire plc for $64 per Share

RADFORD, Va., Feb. 20 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that it has signed a definitive...

New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Conference

RADFORD, Va., Feb. 5 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that it plans to present at the 2007...

James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing

RADFORD, Va., Jan. 25 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that James P. Shaffer has been...

New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of

Launch Expected Q2 2007 BASINGSTOKE, U.K., PHILADELPHIA and RADFORD, Va., Dec. 21 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc...

New River Pharmaceuticals Announces Third Quarter 2006 Results

RADFORD, Va., Nov. 7 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced its financial results for the three...

Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific Meeting

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP; Nasdaq: SHPGY; TSX: SHQ) and its collaborative partner New River...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

New River Pharmaceuticals (MM) (NRPH)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

NRPH Actualités

HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite Indices

New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013

New River Announces Expiration of Hart-Scott-Rodino Waiting Period

New River Pharmaceuticals Announces Year-End Results

Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine

New River Pharmaceuticals to be Acquired by Shire plc for $64 per Share

New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Conference

James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing

New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of

New River Pharmaceuticals Announces Third Quarter 2006 Results

Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific Meeting

New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290

FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHD

New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

New River Pharmaceuticals (MM) (NRPH) Actualités

New River Pharmaceuticals (MM) (NRPH)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

NRPH Actualités

HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite Indices

New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013

New River Announces Expiration of Hart-Scott-Rodino Waiting Period

New River Pharmaceuticals Announces Year-End Results

Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine

New River Pharmaceuticals to be Acquired by Shire plc for $64 per Share

New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Conference

James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing

New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of

New River Pharmaceuticals Announces Third Quarter 2006 Results

Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific Meeting

New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290

FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHD

New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application